Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Z155080000004
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
The guidelines warn, however, that GLP-1 receptor agonist therapy is not indicated for all patients and should be used with caution in patients with a history of significant gastrointestinal disease, such as a diagnosis of gastroparesis, due to a possible exacerbation of the condition with incretin mimetic therapy
Our ISPOR poster aimed to address this gap
It sounds dramatic
Background Inflammatory bowel disease (IBD) is an idiopathic condition characterized by chronic relapsing inflammation in the gastrointestinal tract
US$ 29.81
US$ 26.74
US$ 23.13
US$ 27.11
US$ 24.39
US$ 24.89
US$ 25.21
US$ 27.94
US$ 26.89
